Senexin-A
A selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively; inhibits only p21-induced transcription but not other biological effects of p21, inhibits β-catenin-dependent transcription in HCT116 colon carcinoma cells; suppresses damage-induced tumor-promoting paracrine activities of tumor cells and normal fibroblasts and reverses the increase in tumor engraftment and serum mitogenic activity in mice pretreated with doxorubicin.
Product Specifications
CAS Number
1366002-50-7
Product Name Alternative
Senexin A
Purity
>98% (HPLC)
Solubility
DMSO: ≥100 mg/mL
Smiles
N#CC1=CC2=C (NCCC3=CC=CC=C3) N=CN=C2C=C1
Molecular Formula
C17H14N4
Molecular Weight
274.32
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
6-Quinazolinecarbonitrile, 4-[ (2-phenylethyl) amino]-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
GAcrp30, Recombinant, Mouse (Globular Adipocyte Complement-related Protein of 30kD, apm-1, Adipolean) discontinued